Multiple Myeloma Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | CASI Pharmaceuticals, Carsgen Therapeutics, Cartesian Therapeutics, Gracell Biotechnology Shanghai

Multiple Myeloma Pipeline constitutes 75+ key companies continuously working towards developing 80+ Multiple Myeloma treatment therapies, analyzes DelveInsight.

Multiple Myeloma Overview:

Multiple myeloma (MM) is a disorder involving the uncontrolled proliferation of clonal plasma cells, leading to an excessive production of monoclonal immunoglobulins. If left untreated, this can result in end-organ damage, typically presenting as hypercalcemia, kidney dysfunction, anemia, or bone pain with lytic lesions.

The symptoms, onset age, and progression rate of multiple myeloma vary among individuals. Some patients remain asymptomatic, while others may develop severe complications. Bone pain, particularly in the lower back or ribs, is the most common symptom. Additionally, hypercalcemia, marked by elevated calcium levels in the blood, is another potential indication of the disease.

Request for a detailed insights report on Multiple Myeloma pipeline insights @ https://www.delveinsight.com/report-store/multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Multiple Myeloma Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Multiple Myeloma Therapeutics Market.

Key Takeaways from the Multiple Myeloma Pipeline Report

DelveInsight's Multiple Myeloma pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Multiple Myeloma treatment.
In January 2025, Sanofi announced the results of its Phase III IRAKLIA trial evaluating Sarclisa (isatuximab) for multiple myeloma (MM). Conducted across 252 global sites, the trial involved 531 adult patients who had received at least one prior therapy, including lenalidomide and a proteasome inhibitor. The trial met its co-primary endpoints when Sarclisa was administered subcutaneously via an on-body delivery system (OBDS) in combination with pomalidomide and dexamethasone (Pd).
In September 2024, Johnson & Johnson released findings from the Phase III CARTITUDE-4 trial, demonstrating that its cell therapy, CARVYKTI (ciltacabtagene autoleucel), significantly improved overall survival in multiple myeloma patients. The trial compared CARVYKTI to standard regimens such as pomalidomide, bortezomib, and dexamethasone (PVd) or daratumumab, pomalidomide, and dexamethasone (DPd) in patients previously treated with at least one therapy, including a proteasome inhibitor.
In August 2024, Swiss biopharmaceutical company Opna Bio initiated a Phase I trial for OPN-6602, an EP300/CBP bromodomain inhibitor for multiple myeloma. The first dose was administered at The START Center for Cancer Research in Grand Rapids, Michigan, with plans to enroll up to 130 participants with relapsed or refractory MM at multiple U.S. sites.
In April 2024, Bristol Myers Squibb and 2seventy bio announced the FDA's approval of Abecma® (idecabtagene vicleucel; ide-cel) for adults with relapsed or refractory multiple myeloma after at least two prior therapies. These must include an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and an anti-CD38 monoclonal antibody. Based on the KarMMa-3 trial, this expanded approval allows earlier use for triple-class exposed patients. Abecma is administered as a single infusion, with a recommended dose range of 300 to 510 x 10⁶ CAR-positive T cells.
Key Multiple Myeloma companies such as CASI Pharmaceuticals, Carsgen Therapeutics, Cartesian Therapeutics, Gracell Biotechnology Shanghai Co., Ltd., Sorrento Therapeutics, TeneoOne, Karyopharma Therapeutics, Arcellx, Poseida Therapeutics, Ichnos Sciences, Nerviano Medical Sciences, Bristol Myers Squib, Ascentage Pharma, Ionis Pharmaceuticals, Chongqing Precision Biotech Co., Ltd., CRISPR Therapeutics, AstraZeneca, IGM Biosciences, Novartis, GlaxoSmithKline, Innovent Biologics, Keymed Biociences, Starton Therapeutics, Takeda, Fate Therapeutics, Gilead Sciences, Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd., Janssen Pharmaceutical, Nanjing IASO Biotechnology Co., Ltd., GPCR Therapeutics, Chimerix, and others are evaluating new drugs for Multiple Myeloma to improve the treatment landscape.
Promising Multiple Myeloma pipeline therapies in various stages of development include Zevorcabtagene Autoleucel, Descartes 08, GC012F, CID-103, STI-1492, and others.

Multiple Myeloma Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Multiple Myeloma Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Multiple Myeloma treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Multiple Myeloma market.

Download our free sample page report on Multiple Myeloma pipeline insights @ https://www.delveinsight.com/sample-request/metastatic-prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Multiple Myeloma Emerging Drugs

Zevorcabtagene Autoleucel: Carsgen Therapeutics
Descartes 08: Cartesian Therapeutics
GC012F: Gracell Biotechnology Shanghai Co., Ltd.
CID-103: CASI Pharmaceuticals
STI-1492: Sorrento Therapeutics

Multiple Myeloma Companies

Around 75 key companies are actively developing therapies for multiple myeloma. Among them, Carsgen Therapeutics has a drug candidate in the most advanced stage, classified as Registered.

DelveInsight's report covers around 80+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Multiple Myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Multiple Myeloma Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Multiple Myeloma Therapies and Key Companies: Multiple Myeloma Clinical Trials and advancements @ https://www.delveinsight.com/report-store/multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Multiple Myeloma Pipeline Therapeutic Assessment
• Multiple Myeloma Assessment by Product Type
• Multiple Myeloma By Stage
• Multiple Myeloma Assessment by Route of Administration
• Multiple Myeloma Assessment by Molecule Type

Download Multiple Myeloma Sample report to know in detail about the Multiple Myeloma treatment market @ Multiple Myeloma Therapeutic Assessment @ https://www.delveinsight.com/sample-request/metastatic-prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Multiple Myeloma Current Treatment Patterns
4. Multiple Myeloma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Multiple Myeloma Late-Stage Products (Phase-III)
7. Multiple Myeloma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Multiple Myeloma Discontinued Products
13. Multiple Myeloma Product Profiles
14. Multiple Myeloma Key Companies
15. Multiple Myeloma Key Products
16. Dormant and Discontinued Products
17. Multiple Myeloma Unmet Needs
18. Multiple Myeloma Future Perspectives
19. Multiple Myeloma Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Multiple Myeloma Pipeline Reports Offerings: https://www.delveinsight.com/report-store/multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.